Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
06.11.24
/
50%
€47.00
Target price
06.11.25
€71.64
Performance (%)
-42.98%
End price
07.11.25
€26.80
Summary
This prediction ended on 07.11.25 with a price of €26.80. Massive losses of -42.98% were the result for the BUY prediction by Royal_Bank_of_Canada. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -7.643% | -7.643% | -30.952% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten
Stopped prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€49.00
26.09.24
26.09.24
€69.10
26.09.25
26.09.25
-49.39%
27.09.25
27.09.25
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€41.20
22.04.24
22.04.24
€72.35
22.04.25
22.04.25
-22.82%
23.04.25
23.04.25